AI Article Synopsis
- S100A9 is found in different cell types and is linked to cancer development and progression, but its role in hepatocellular carcinoma (HCC) is not well understood.
- The study utilized The Cancer Genome Atlas (TCGA) to analyze S100A9 expression in HCC, revealing that higher levels were associated with poorer patient prognosis and increased recurrence rates.
- Immunohistochemistry identified S100A9-expressing cells, primarily CD15 neutrophils and CD68 macrophages, in both tumor and adjacent tissues, indicating that S100A9 could be a valuable marker for predicting outcomes in HCC patients.
Article Abstract
S100A9 is differentially expressed in various cell types and is associated with the development, progression and metastasis of various cancers. However, the expression, distribution, and clinical significance of S100A9 in hepatocellular carcinoma (HCC) remain unclear. In the present study, The Cancer Genome Atlas (TCGA) database was used to examine gene expression in HCC; we found that expression was associated with HCC prognosis. In addition, S100A9 protein expression was assessed by immunohistochemistry analysis of tissues from 382 HCC patients. We found that the infiltration of S100A9 cells in both tumor and nontumor tissues could predict poor overall survival ( = 0.0329, tumor; = 0.0003, nontumor) and a high recurrence risk ( = 0.0387, tumor; = 0.0015, nontumor) in our tissue microarray analysis. Furthermore, immunofluorescence double staining revealed that the primary S100A9-expressing cells in adjacent nontumoral tissue were CD15 neutrophils, and both CD68 macrophages and CD15 neutrophils expressed S100A9 in HCC tumor tissues. Taken together, the results suggest that high S100A9 cell density predicts a poor prognosis in HCC patients, and S100A9 expression could potentially serve as an independent prognostic marker for HCC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266308 | PMC |
| http://dx.doi.org/10.18632/aging.203162 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Plasma S100A8/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.
Sci Rep
January 2025
Department of Allergy and Respiratory Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, Japan.
Blood-based predictive markers for the efficacy of immune checkpoint inhibitors (ICIs) have not yet been established. We investigated the association of the plasma level of S100A8/A9 with the efficacy of immunotherapy. We evaluated patients with unresectable stage III/IV or recurrent non-small cell lung cancer (NSCLC) who were treated with ICIs at Okayama University Hospital.
View Article and Find Full Text PDFUnveiling the Molecular Mechanisms of Rosacea: Insights From Transcriptomics and In Vitro Experiments.
J Cosmet Dermatol
January 2025
Department of Plastic and Cosmetic Surgery, Hubei Provincial Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, China.
Background: Rosacea is a prevalent inflammatory skin condition, but its molecular mechanisms and treatment responses remain poorly understood.
Aims: This study aims to investigate the molecular mechanisms underlying rosacea and explore drug response through transcriptomic analysis and in vitro experiments.
Patients/methods: We performed high-throughput RNA sequencing to analyze gene expression patterns in rosacea patients.
The diagnostic value and clinical correlations of bone marrow supernatant S100A8 and S100A9 in myelodysplastic neoplasms.
Cytokine
January 2025
Department of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China. Electronic address:
Purpose: Myelodysplastic neoplasms (MDS) are heterogeneous neoplasms that originate from bone marrow (BM) hematopoietic stem cells. S100A8 and S100A9 (S100A8/9) are crucial molecules involved in the innate immune pathogenesis of MDS. This study aimed to explore the value of these molecules in the differential diagnosis of MDS, and analyze the correlations between their concentrations and clinical characteristics.
View Article and Find Full Text PDFMPCD Index for Hepatocellular Carcinoma Patients Based on Mitochondrial Function and Cell Death Patterns.
Int J Mol Sci
December 2024
Chongqing Key Laboratory of Big Data for Bio Intelligence, Chongqing University of Posts and Telecommunications, Chongqing 400065, China.
Hepatocellular carcinoma (HCC) is a highly heterogeneous cancer with a poor prognosis. During the development of cancer cells, mitochondria influence various cell death patterns by regulating metabolic pathways such as oxidative phosphorylation. However, the relationship between mitochondrial function and cell death patterns in HCC remains unclear.
View Article and Find Full Text PDFMachine learning approach identifies inflammatory gene signature for predicting survival outcomes in hepatocellular carcinoma.
Sci Rep
December 2024
Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA.
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, often linked to chronic inflammation. Our study aimed to probe inflammation pathways at the genetic level and pinpoint biomarkers linked to HCC patient survival.
Methods: We analyzed gene transcriptome data from 246 resectable stage I and II HCC patients from The Cancer Genome Atlas (TCGA).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!